<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004688</url>
  </required_header>
  <id_info>
    <org_study_id>199/13310</org_study_id>
    <secondary_id>EUSM-FDR001274</secondary_id>
    <nct_id>NCT00004688</nct_id>
  </id_info>
  <brief_title>Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FDA Office of Orphan Products Development</source>
  <brief_summary>
    <textblock>
      OBJECTIVES:

      I. Assess the clinical response of patients with refractory or recurrent brain neoplasms
      treated with carmustine, streptozocin, and mercaptopurine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE:

      Patients receive mercaptopurine IV on days 1-3, carmustine by continuous infusion on days
      3-5, and streptozocin IV over 20 minutes on days 2-5. Patients receive treatment every 42
      days, for up to 4 courses.

      Completion date provided represents the completion date of the grant per OOPD records
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1996</start_date>
  <completion_date>July 1998</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>35</enrollment>
  <condition>Anaplastic Astrocytoma</condition>
  <condition>Anaplastic Oligodendroglioma</condition>
  <condition>Mixed Gliomas</condition>
  <condition>Glioblastoma Multiforme</condition>
  <condition>Recurrent Brain Tumor</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mercaptopurine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>streptozocin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics-- Histologically proven refractory or recurrent brain neoplasms
        Glioblastoma multiforme Anaplastic astrocytoma Gliosarcoma Anaplastic oligodendroglioma
        Mixed anaplastic glioma Unequivocally progressive primary brainstem tumors following
        primary therapy Measurable disease --Prior/Concurrent Therapy-- Biologic therapy: Not
        specified Chemotherapy: At least 4 weeks since prior chemotherapy At least 6 weeks since
        prior nitrosoureas or mitomycin Endocrine therapy: Not specified Radiotherapy: Prior
        radiotherapy allowed Surgery: Prior surgery allowed --Patient Characteristics-- Age: Not
        specified Performance status: ECOG 0-2 Karnofsky 60-100% Hematopoietic: Granulocyte count
        at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than
        2.0 mg/dL SGOT no greater than 4 times normal Renal: Creatinine no greater than 2.0 mg/dL
        Pulmonary: FEV1 greater than 1 L if symptomatic pulmonary disease present Other: No other
        concurrent malignancies Not pregnant or lactating Negative pregnancy test Fertile patients
        must use effective contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark R. Gilbert</last_name>
    <role>Study Chair</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <verification_date>March 1999</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2000</study_first_submitted>
  <study_first_submitted_qc>February 24, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2000</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult brain stem glioma</keyword>
  <keyword>adult brain tumor</keyword>
  <keyword>adult glioblastoma multiforme</keyword>
  <keyword>adult infiltrating astrocytoma</keyword>
  <keyword>brain tumor</keyword>
  <keyword>genetic condition</keyword>
  <keyword>miscellaneous sites/terms</keyword>
  <keyword>mixed gliomas</keyword>
  <keyword>nervous tissue tumors</keyword>
  <keyword>oncologic disorders</keyword>
  <keyword>rare disease</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Streptozocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

